Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 3,125 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.00, for a total value of $40,625.00. Following the completion of the transaction, the chief financial officer now directly owns 144,301 shares of the company’s stock, valued at approximately $1,875,913. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 1.32% during mid-day trading on Friday, hitting $12.69. 436,041 shares of the company’s stock traded hands. BioCryst Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $13.33. The stock’s 50-day moving average is $10.87 and its 200-day moving average is $10.00. The company’s market cap is $762.2 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.17) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was down 2.8% on a year-over-year basis. Analysts expect that BioCryst Pharmaceuticals will post $-0.75 EPS for the current fiscal year.

BCRX has been the subject of a number of recent research reports. Analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. They now have a $17.00 price target on the stock, down previously from $19.00. Separately, analysts at HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $21.00 to $24.00 in a research note on Friday, May 30th. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of BioCryst Pharmaceuticals from $18.00 to $20.00 in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. BioCryst Pharmaceuticals has a consensus rating of “Buy” and an average target price of $18.13.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.